Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

BACKGROUND: Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS: Patient...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Breast Cancer
Main Authors: Irvin, William J., Orlowski, Robert Z., Chiu, Wing-Keung, Carey, Lisa A., Collichio, Frances A., Bernard, Philip S., Stijleman, Inge J., Perou, Charles, Ivanova, Anastasia, Dees, E. Claire
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5830095/
https://ncbi.nlm.nih.gov/pubmed/21147690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CBC.2010.n.061
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares